Adaptive Biotechnologies Corp vs Booz Allen Hamilton Holding Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Booz Allen Hamilton Holding Corporation trades at $78.54 (market cap $9.45B). The key difference: Booz Allen Hamilton Holding Corporation is far larger — about 2.3× Adaptive Biotechnologies Corp's market cap, and Booz Allen Hamilton Holding Corporation pays a 3% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | BAH | |
|---|---|---|
Market Cap | $4.04B | $9.45B |
Sector | Health | Industrials |
52-Week High | $25.45 | $111.63 |
52-Week Low | $12.30 | $59.71 |
Enterprise Value | $4.10B | $13.07B |
Dividend Yield | — | 3% |
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →